Evidence map›Paper›PMID 1450640›Full record

ReviewThe Clinical investigator1992

Mesangial cells in the pathogenesis of progressive glomerular disease in animal models.

J Floege, R J Johnson, W G Couser

Abstract readReview
PubMed Publisher
In one paragraph

Review in The Clinical investigator, 1992. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.2field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 62 citations in OpenAlex.

  1. Article
  2. Improving kidney targeting: The influence of nanoparticle physicochemical properties on kidney interactions.Journal of controlled release : official journal of the Controlled Release Society · 2021
    Review
  3. Article
  4. Article
  5. The aging kidney and the nephrotoxic effects of mercury.Journal of toxicology and environmental health. Part B, Critical reviews · 2017
    Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Mediation of immune glomerular injury.The Clinical investigator · 1993
    Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

J FloegeAbteilung Nephrologie, Medizinische Hochschule Hannover.
R J Johnson
W G Couser
University of Washington · USMedizinische Hochschule Hannover · DE

Funding

DISTAL COMPLEMENT COMPONENTS IN IMMUNE RENAL INJURYR01DK034198 · NIDDK · UNIVERSITY OF WASHINGTON · PI COUSER, WILLIAM G · 1986 to 2001
$569k
PLATELETS IN IMMUNE GLOMERULAR INJURYR01DK043422 · NIDDK · UNIVERSITY OF WASHINGTON · PI JOHNSON, RICHARD JOSEPH · 1991 to 1999
–
MYELOPEROXIDASE-H202-HALIDE SYSTEM IN GLOMERULAR INJURYR29DK039068 · NIDDK · UNIVERSITY OF WASHINGTON · PI JOHNSON, RICHARD JOSEPH · 1987 to 1991
–
DISTAL COMPLEMENT COMPONENTS IN IMMUNE RENAL INJURYR37DK034198 · NIDDK · UNIVERSITY OF WASHINGTON · PI COUSER, WILLIAM G · 1990 to 1997
–
MESANGIAL RESPONSE TO INJURYR55DK043422 · NIDDK · UNIVERSITY OF WASHINGTON · PI JOHNSON, RICHARD JOSEPH · 1996 to 1996
–
NIDDK NIH HHS DK 34198NIDDK NIH HHS DK 39068NIDDK NIH HHS DK 43422
6 · The paper itself

Abstract

Increasing evidence supports a role for glomerular mesangial cell proliferation and over-production of extracellular matrix by mesangial cells in the development of focal or diffuse glomerulosclerosis. Experimental data obtained mainly in the chronic progressive remnant kidney model and in the acute mesangioproliferative anti-Thy 1.1 glomerulonephritis in rats have shed some insights into the factors governing mesangial cell proliferation and matrix synthesis in vivo. In these experimental models, mesangial cell activation can be demonstrated early in the course of disease as exemplified by the de novo expression by the mesangial cell of a smooth muscle "specific" actin isotype (i.e., alpha-smooth muscle actin). Following mesangial cell activation, cellular proliferation ensues both in the acute anti-Thy 1.1 model and, to a lesser degree, in the chronic remnant kidney model. While a multitude of mitogens for mesangial cells has been proposed on the basis of in vitro experiments, the factors involved in the regulation of mesangial cell proliferation in vivo remain largely undefined. Three growth factors which may have important roles in the in vivo mesangioproliferative response are platelet-derived growth factor (PDGF), basic fibroblast growth factor (bFGF), and transforming growth factor-beta (TGF-beta). All three cytokine growth factors are present in various inflammatory cells as well as in mesangial cells themselves, thereby allowing these factors to mediate cell proliferation by either paracrine and/or autocrine pathways. In vivo studies show that PDGF, bFGF, and TGF-beta participate in the mesangial cell proliferation and/or the mesangial matrix expansion that follows mesangial cell injury with anti-Thy 1.1 antibody.(ABSTRACT TRUNCATED AT 250 WORDS)

Indexed as

AnimalsCell DivisionCollagenDisease Models, AnimalExtracellular Matrix ProteinsGlomerular MesangiumGlomerulosclerosis, Focal SegmentalGrowth SubstancesCollagenExtracellular Matrix ProteinsGrowth Substances

Identifiers

PMID1450640
OpenAlexW2016225384

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.